Webcasts Event RSS
Upcoming Events Past Events
Wells Fargo 2019 Healthcare Conference
September 4, 2019
View the live Webcast
Canaccord Genuity 39th Annual Growth Conference
August 8, 2019
View the live Webcast
Halozyme to Host Second Quarter 2019 Financial Results Conference Call
August 6, 2019
View the live Webcast

Investor Materials

Thumb Date Download
July 20, 2018 Corporate Presentation 996 KB
January 1, 2018 2018 Annual Report 939 KB
December 31, 2017 2017 Annual Report 3.18 MB
July 24, 2016 2016 Annual Report 4.75 MB
July 23, 2016 2015 Annual Report 5.24 MB
July 21, 2016 2014 Annual Report 2.13 MB

Recent News

Date Title Press Release RSS
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology 09/13/19
Halozyme To Participate In 2019 Wells Fargo Healthcare Conference 08/26/19
Halozyme Reports Second Quarter 2019 Results 08/06/19
Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference 07/25/19
See More

Stock Quote

HALO (NASDAQ) $16.29 -0.13 -0.79% Volume: 966,629 Pricing delayed 20 minutes September 19, 2019

Investor Contacts

Al Kildani
Vice President, Investor Relations
& Corporate Communications
Phone: 858-704-8122
Email: akildani@halozyme.com
media@halozyme.com
ir@halozyme.com

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

September 13, 2019 Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
August 26, 2019 Halozyme To Participate In 2019 Wells Fargo Healthcare Conference
August 6, 2019 Halozyme Reports Second Quarter 2019 Results
Copyright © 2015-2017 . Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.24.1.2

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok